Related Experiment Video
Updated: Jun 27, 2026
09:05
In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition
Published on: August 20, 2016
Corneal endothelial cell loss after mitomycin C-augmented trabeculectomy.
Thomas Storr-Paulsen1, Jens Christian Norregaard, Shakil Ahmed
1Department of Ophthalmology, Frederiksberg University Hospital, Frederiksberg, Denmark.
Journal of Glaucoma
|December 19, 2008
Summary
Mitomycin C (MMC)-augmented trabeculectomy caused significant corneal endothelial cell loss immediately after surgery. However, no further cell loss occurred between 3 and 12 months, indicating no prolonged toxic effect.
Area of Science:
- Ophthalmology
- Glaucoma Surgery
- Corneal Science
Background:
- Trabeculectomy is a common glaucoma surgery.
- Mitomycin C (MMC) is used to enhance trabeculectomy outcomes.
- The effect of MMC on the corneal endothelium requires further investigation.
Purpose of the Study:
- To evaluate the impact of MMC-augmented trabeculectomy on corneal endothelial cells.
- To assess endothelial cell density, cell size variation, hexagonal cell percentage, and corneal thickness.
- To determine changes at 3 and 12 months post-surgery.
Main Methods:
- Prospective, observational clinical study.
- 14 eyes of 14 open-angle glaucoma patients were analyzed.
- Corneal endothelium parameters were measured pre- and post-surgery.
Main Results:
- A significant decrease in endothelial cell density was observed post-surgery (9.5% at 3 months, 10.0% at 12 months).
- No significant progression of cell loss occurred between 3 and 12 months.
- Endothelial cell morphology (size variation, hexagonal percentage) had not stabilized by 12 months.
Conclusions:
- MMC-augmented trabeculectomy leads to immediate corneal endothelial cell loss.
- No prolonged toxic effect of MMC on the corneal endothelium was detected.
- Active endothelial adaptations occur between 3 and 12 months post-surgery.
